PainCeptor receives IRAP assistance

PainCeptor Pharma Corp has received $480,000 in funding from the Industrial Research Assistance Program to further develop its drug development program for pain-related conditions such as arthritis and cancer. The contribution agreement will be used to advance PainCeptor's R&D for the design and synthesis of low molecular weight compounds as part of its ASIC 3 (acid-sensing ion channels) program. The project will see the Montreal-based firm collaborate with a scientific team led Dr Prabhat Arya, at the National Research Council's Steacie Institute for Molecular Sciences in Ottawa. ASICs are key pain sensors within the peripheral nervous system, allowing pain treatment without dealing with the central nervous system. PainCeptor's president/ CEO is Dr Louis Lamontagne....